amitriptyline hydrochloride 10mg/5ml oral solution
syri limited t/a thame laboratories - amitriptyline hydrochloride - oral solution - 10 mg/5ml - antidepressants - it is indicated for the treatment of: symptoms of depression (especially where sedation is required); nocturnal enuresis where organic pathology is excluded
amitriptyline hydrochloride 25mg/5ml oral solution
syri limited t/a thame laboratories - amitriptyline hydrochloride - oral solution - 25mg/5ml - antidepressants - it is indicated for the treatment of: symptoms of depression (especially where sedation is required); nocturnal enuresis where organic pathology is excluded.
amitriptyline hydrochloride 10mg/5ml oral solution
syri limited, t/a thame laboratories - amitriptyline hydrochloride - oral solution - 10mg/5ml - antidepressants - amitriptyline is indicated for the treatment of: symptoms of depression (especially where sedation is required). nocturnal enuresis where organic pathology is excluded.
atenolol
syri limited, t/a thame laboratories - atenolol - oral solution - 5 mg/ml - atenolol - beta-blocking agents, plain, selective - management of hypertension management of angina management of cardiac arrhythmias myocardial infarction. early intervention in the acute phase
furosemide 8mg/ml oral solution
syri limited, t/a thame laboratories - furosemide - oral solution - 8 milligram(s)/millilitre - sulfonamides, plain; furosemide - high-ceiling diuretic sulfonamide - furosemide is indicated in all conditions requiring prompt diuresis in patients who are unable to take solid dose forms. indications include cardiac, pulmonary, hepatic and renal oedema, peripheral oedema due to mechanical obstruction or venous insufficiency and hypertension.
furosemide 10mg/ml oral solution
syri limited, t/a thame laboratories - furosemide - oral solution - 10 milligram(s)/millilitre - sulfonamides, plain; furosemide - high-ceiling diuretic sulfonamide - furosemide is indicated in all conditions requiring prompt diuresis in patients who are unable to take solid dose forms. indications include cardiac, pulmonary, hepatic and renal oedema, peripheral oedema due to mechanical obstruction or venous insufficiency and hypertension.
furosemide 4mg/ml oral solution
syri limited, t/a thame laboratories - furosemide - oral solution - 4 milligram(s)/millilitre - sulfonamides, plain; furosemide - high-ceiling diuretic sulfonamide - furosemide is indicated in all conditions requiring prompt diuresis in patients who are unable to take solid dose forms. indications include cardiac, pulmonary, hepatic and renal oedema, peripheral oedema due to mechanical obstruction or venous insufficiency and hypertension
amitriptyline hydrochloride 50mg/5ml oral solution
syri limited, t/a thame laboratories - amitriptyline hydrochloride - oral solution - 50 mg/5ml - non-selective monoamine reuptake inhibitors; amitriptyline - antidepressants - it is indicated for the treatment of: symptoms of depression (especially where sedation is required), nocturnal enuresis where organic pathology is excluded.
levetiracetam thame 100 mg/ml oral solution
syri limited, t/a thame laboratories - levetiracetam - oral solution - 100 milligram(s)/millilitre - other antiepileptics; levetiracetam
clobazam thame 5mg/5ml oral suspension
syri limited, t/a thame laboratories - clobazam - oral suspension - 5 mg/5ml - benzodiazepine derivatives; clobazam